Residual CTCAE ? Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy
Prior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy, or radiation must have recovered to grade =< 1 with the exception of alopecia and the criteria outlined
Patients must have recovered to =< grade 2 following a significant adverse event or toxicity attributed to previous anti-cancer treatment except neurotoxicity which must be =< grade 1
Prior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy and radiation therapy must have recovered to grade =< 1 with the exception of alopecia, ototoxicity and neuropathy
CNS toxicity =< grade 2
Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 (except hemoglobin value) and/or that is progressing in severity, except alopecia
Resolution of toxicity from prior anti-cancer therapy, to NCI CTCAE v4.03 Grade 0 or 1, except for alopecia. Subjects may be enrolled if their toxicity is determined to be irreversible and will not put them at undue risk from study treatment, based on the Investigator's assessment.
CNS toxicity =< grade 2
At least two weeks from last systemic therapy for breast cancer, with recovery of all treatment related toxicity to grade 1 or less; subjects with =< grade 2 neuropathy are an exception to this criterion
Presence of ? CTCAE Grade 2 toxicity due to prior cancer therapy.
Participants who have not recovered to =< CTCAE grade 1 or baseline from toxicity as a result of previous cancer treatment prior to entering the study (with the exception of alopecia and peripheral neuropathy which can be =< grade 2)
CTCAE Version 4, Grade 4 non-hematological toxicity (except for alopecia, nausea, vomiting).
Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy
Grade >= 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy
Subjects with known persistent (> 4 weeks) >= grade 2 toxicity from prior cancer therapy
Patients with grade > 1 neuropathy or grade > 1 toxicity (except alopecia or anorexia) from prior therapy
Grade > 1 toxicity from prior therapy (except alopecia or anorexia)
Grade 3 or higher toxicity effects from previous treatment with immunotherapy
Patients with history of any grade 4 toxicity during previous anti PD-1 treatment or history of grade 3 or higher pneumonitis
Must have discontinued radiotherapy at least 14 days with resolution of any toxicity to Grade 1 or better prior to the start of treatment.
Grade >= 2 toxicity (other than alopecia) continuing from prior anticancer therapy, including radiation
Neuropathy as residual toxicity after prior antitumor therapy Grade >2
Patients who experienced grade 3 or above skin toxicity from prior EGFR inhibiting therapy
Patients who have experienced grade 3 or above toxicity from prior anti-PD1 therapy
Residual or ongoing ? Grade 3 toxicity from chemotherapy
have inadequate recovery* from adverse events resulting from previously-administered anti-cancer therapies; [*Note: Unless more specifically defined in Inclusion Criteria 6, 7 and 8 above, adequate recovery is defined as improvement to ? Grade 2 for any other hematologic toxicity and for peripheral neuropathy, and improvement to ? Grade 1 for any other non-hematologic toxicity.]
Recovered from any prior treatment related toxicity to at least Grade 1 with exception of Grade 2 alopecia or other Grade 2 toxicity with prior approval of the Medical Monitor
Subjects with history of grade 3 toxicity or use of infliximab with prior immunotherapy
Presence of grade 3 or greater toxicity from the previous treatment.
Ongoing clinically significant toxicity (Grade 2 or greater) associated with prior treatment (including radiotherapy or surgery).
At least 4 weeks (wks) since prior radiation or surgery with full recovery (no persistent toxicity >= grade 1)
Hydroxyurea may be used to control leukocytosis, provided that it is without grade > 2 toxicity, and can be taken until start of therapy
Ongoing acute treatment-related toxicity associated with a previous therapy greater than grade 1 except for grade 2 alopecia or neuropathy.
To be eligible for study treatment, toxicity from prior treatment must recover to Grade ? 1, except for alopecia
Has experienced grade 4 toxicity on treatment with prior radiation
Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia);
At least 4 weeks from end of surgery, chemotherapy, or radiotherapy with resolution of any toxicity to grade 1 or less, excluding alopecia\r\n* NOTE: There is no washout for patients who have undergone cosmetic surgeries
At least 14 days from the last therapy dose or 5 half-lives (whichever is shorter), and resolution of toxicity related to the last therapy, excluding grade 2 or less peripheral neuropathy and alopecia; for radiation therapy, a minimum of 2 weeks and resolution of all acute toxicity will be required
To be eligible for study treatment, toxicity from prior treatment must recover to Grade ? 1, except for alopecia
Patients who have residual toxicity(-ities) from previous anti-cancer treatment(s) that is/are clinically significant or > grade 1 are excluded; those whose toxicity(-ities) improved to grade 1 or better will be eligible
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia); any immuno-oncology (IO) related adverse events must be =< grade 1 to be eligible
Any clinically significant toxicity from prior therapy must have improved to grade 0 or grade 1
Skin toxicity no greater than grade 1
Prior grade 4 toxicity attributed to cytarabine
Existing severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade 3, except for grade 3 hematologic toxicity
At least 4 weeks since prior surgery with full recovery (no persistent toxicity >= grade 1)
Patient who has had radiotherapy within 1 week (or unresolved radiation-related toxicities), chemotherapy within 2 weeks or 5 half-lives, whichever is longer (6 weeks for nitrosoureas, mitomycin C or bevacizumab), anti-cancer monoclonal antibody for direct anti-neoplastic treatment within 3 weeks, or who has not recovered from toxicity due to previous agents administered. If the patient has residual toxicity from prior treatment, toxicity must be =< grade 1 (except for neuropathy and alopecia)
Any previous history of >= grade 3 toxicity to dasatinib
If the patient has residual toxicity from prior treatment, toxicity must be =< grade 1
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopecia
Recovery to Grade 1 of any clinically significant toxicity attributed to prior anticancer therapy prior to initiation of study drug administration
Severe major organ toxicity: specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less; a grade 3 hearing deficit is acceptable
Otherwise, all toxicity at study entry ? Grade 1 by NCI CTC v4.0.
Grade > 1 toxicity from prior therapy (except alopecia or anorexia)
Has persistent, clinically significant > Grade 1 non-hematologic toxicity from prior AML therapies
Grade > 1 toxicity from prior therapy (except alopecia or anorexia).
Patients will be ineligible if they have a baseline neurologic toxicity of grade 3 or greater
Skin toxicity =< grade 1
Grade 2 or greater toxicity from prior therapy
Patients who have a CNS toxicity > grade 2 are not eligible
Omission of cytotoxic chemotherapy or other systemic therapy of the malignancy for >= 4 weeks prior to entry into the trial; patients must be >= 4 weeks since major surgery, radiotherapy, or biotherapy/targeted therapies and recovered from the toxicity of prior treatment to =< Common Toxicity Criteria (CTC) grade 1, exclusive of grade 2 alopecia, fatigue, lymphopenia, CD4+ circulating T cells, white blood count (WBC) or bilirubin
Resolution of grade >= 2 toxicity from prior therapy (other than alopecia)
Persistent, clinically significant > Grade 1 non-hematologic toxicity from prior AML therapy.
Any ongoing toxicity from prior anti-cancer therapy that is greater than grade 1 and/or that is progressing in severity, except alopecia
Patients must not have any known, persistent (> 4 weeks), ?Grade 3 hematologic toxicity during the last cancer therapy. Patients must not have any known, persistent (>4 weeks), ? Grade 3 fatigue during the last cancer therapy.
Current grade >= 1 toxicity (except alopecia) from prior therapy
Failure to recover (to CTCAE Version 4.0 Grade 0 or Grade 1) from acute non hematologic toxicity (except all grades of alopecia or Grade 2 or lower neuropathy), due to previous therapy, prior to Screening.
Subjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to prior anti-cancer treatment are excluded
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia)
Ongoing toxicity due to a prior therapy, unless returned to baseline or Grade 1. Grade 2 toxicities (e.g., alopecia or peripheral neuropathy) that are not likely to increase the subject's safety risk while receiving trial treatment may be accepted after Sponsor approval.
Minimal or no ongoing toxicity from immediately prior therapy according to specific appropriate criteria. Mild ongoing toxicity is allowed in case of alopecia, skin toxicity, fatigue and/or finger numbness or tumbling.
No neurosensory or neuromotor toxicity >= grade 2 at the time of registration
Grade >1 toxicity from prior therapy (except alopecia or anorexia).
Current Grade greater than (>) 1 toxicity (except alopecia and anorexia) from prior therapy
Lack of recovery from all toxicity from previous therapy to grade 1 or baseline
Uncontrolled grade 2 or greater toxicity except alopecia
Presence of grade 3 or greater toxicity from the previous treatment
known and persistent (>4 weeks) >/= grade 3 toxicity or fatigue from prior cancer treatment.
Toxicity of ? Grade 2 from prior anticancer therapy
Patients must be at least 2 weeks from prior chemotherapy, including biologics or targeted therapy (i.e. everolimus), or radiotherapy, or any investigational drug product, with adequate recovery of toxicity to baseline, or grade < 1, with the exception of alopecia and hot flashes; there is no washout period for prior endocrine therapy
Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy
Grade ? 2 toxicity (other than alopecia).
Patients with > grade 1 neurologic toxicity at the time of treatment
Patients will be ineligible if they have a baseline neurologic toxicity of grade 3 or greater
Grade ? 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation.
Any ongoing toxicity related to prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (exceptions include alopecia, fatigue, and hematologic toxicities)
Any systemic therapy associated toxicity should be grade 1 or less
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopecia
Any ongoing toxicity from prior hormonal therapy that is > grade 1 and/or that is progressing in severity
Residual toxicity resulting from previous therapy (for example, hematologic, cardiovascular, or neurologic toxicity that is Grade >/=2). Alopecia is permitted
Completed > 80% of the prescribed radiation therapy and concurrent temozolomide according to the Stupp regimen without grade 3 or 4 hematologic toxicity
Patient must not be experiencing any ongoing toxicity from prior anti-cancer therapy that is > grade 1 or that is progressing in severity, except alopecia
Any previous history of >= grade 3 toxicity to Dasatinib
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopecia
Any history of previous >= grade 3 toxicity attributable to erlotinib (except dermatological toxicity)
Patients must be at least 2 weeks from prior chemotherapy or radiotherapy, or any investigational drug product with adequate recovery of toxicity to baseline, or grade =< 1, with the exception of alopecia and hot flashes; there is no washout period for prior endocrine therapy
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity
Any ongoing toxicity from prior investigational therapy that is > grade 1 and/or that is progressing in severity, except alopecia
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopecia
EXPANSION COHORT ONLY: Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity; hypothyroidism treated with medication is not excluded if TSH is within normal limits
Any unrecovered toxicity reactions of CTCAE version 4.03 > grade 1 caused by any previous therapy (excluding alopecia and neurotoxicity < grade 2)
PRIOR TO MOBILIZATION THERAPY: Resolution of grade III-IV toxicity associated with pre-transplant therapy
Failure to recover to Grade 0 or Grade 1 from acute non-hematologic toxicity due to previous therapy, prior to screening (with the exception of alopecia).
Persistence of toxicity from previous chemo and/or radiotherapy > grade 2
Patients who have toxicity from last prior therapy that has not recovered to at least Grade 1, with the exception of Grade 2 alopecia
Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.
Current Grade greater than (>) 1 toxicity (except alopecia and anorexia) from prior therapy or Grade >1 neuropathy from any cause
Participant with ? Grade 2 (CTCAE v 4.0-JCOG) persistent symptoms and objective findings due to the toxicity attributable to prior treatment with antitumor effect (except alopecia).
Lack of recovery from all toxicity from previous therapy to grade 1 or baseline
Patients with chronic grade 1 or 2 toxicity may be eligible at the discretion of the principal investigator if the condition has been stable, and not worsening, for at least 30 days; patients with ongoing alopecia of any grade will be eligible
Toxicity (except alopecia and anorexia) from prior therapy or neuropathy of grades >
Prior clinically significant grade 3-4 non-hematological toxicity to high dose Ara-C or grade ? 2 of neurological toxicity.
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; if the patient has residual toxicity from prior treatment, toxicity must be =< grade 1 (or =< grade 2 for peripheral neuropathy and/or alopecia)
Residual toxicity of > grade 1 from prior therapy
Must not be experiencing a Grade 3 or 4 toxicity from previous anti-cancer treatment
Current Grade >/= 2 toxicity (except for alopecia, anorexia and fatigue) from prior therapy or Grade >/= 2 neuropathy
Adequate recovery (to at least Grade 1) from toxicity of prior therapy as follows:
Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity
Any on-going toxicity from prior anti cancer therapy except alopecia;
At least a 2-week recovery from prior therapy toxicity.
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopecia
Reduction of any acute toxicity from radiation treatment to grade 1
Have unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment, with the exception of alopecia and ?Grade 1 peripheral neuropathy according to the NCI CTCAE v4.03. Clinical judgment by the investigator is allowed to determine if Grade 1 fatigue at screening is residual toxicity from prior treatment or is a symptom of the patient's general condition or disease. The investigator and Medical Monitor will discuss the eligibility of patients with baseline toxicity.
Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade less than or equal to (</=) 1 prior to study entry, with the exception of alopecia
Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy
PHASE I: Cardiac, pulmonary, gastrointestinal and neurologic toxicity should all be =< grade 2
Major organ toxicity including cardiac, pulmonary, gastrointestinal and neurologic toxicity more than grade 2
Patient must not have any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopecia
Residual toxicity due to previous anticancer therapy with no return to baseline or =< Grade 1 (except alopecia) according to CTCAE V4.03
Resolution of treatment-related toxicity to < grade 1; alopecia and cutaneous toxicity are allowed < grade 2
grade 3 to 4 nonhematologic toxicity that does not resolve with adequate intervention
grade 4 hematologic toxicity lasting more than 7 days, or a documented inability to sustain the TKI therapy because of recurrent grade 3 or 4 hematologic toxicity with re-initiation of the same therapy
any grade 2 or greater toxicity that is unacceptable to the patient
Failure to recover from Grade 3 or 4 toxicity from previous treatment
Failure to recover from acute non hematologic toxicity (except alopecia or Grade 2 or lower neuropathy), due to previous therapy, prior to Screening.
